Creo Medical opens new US headquarters as it focuses on market

The AIM-traded firm said the space was designed to support its global growth and focus in the “key” US market, with a learning centre and a fully-equipped laboratory for clinical development and training purposes, which it said would support its education-led commercialisation strategy.

US customer service, finance, product logistics, distribution and other day-to-day functions would also be based in the Danbury office.

Located north-east of New York City, Creo said the office's proximity to international airports provided “convenient access” for visiting clinicians and members of staff.

“We are delighted and proud to have opened our first United States facility, illustrating our commitment to growth and our focus on the key US market,” said chief executive officer Craig Gulliford.

“These new premises will provide an excellent working environment for our US team and a platform to attract further talent in this key region of the US market.”

Over the past 18 months, Creo had established a direct commercial team in the US, led by “experienced and successful” leaders in market development.

The company also had a US director of clinical education, assisted by clinical support specialists, responsible for ensuring safe and effective use of its product platform and devices.

Creo said its ‘Croma’ energy generator platform was in place at a number of academic institutions across the US, with key opinion leaders trained through its clinical education programme.

Those centres had treated their first patients in the US, and had been identified as ‘centres of excellence’ for the operation of the firm’s clinical education programme.

They would be key training sites to educate the second wave of US clinical users, Creo explained, adding that it intended to increase the number of US installations and training centres to support the scaling of its presence in the country.

“Since my appointment in August last year, I have been busy assembling an experienced team to help capitalise on our continued evolution and expansion as a leading medical device company,” said chief commercial officer David Woods.

“The opening of this clinical training and commercial support facility in the US represents the next phase in our planned and sustained development and further illustrates our growth and focus in the region, which gives even greater access to another important market.”

At 1041 BST, shares in Creo Medical were up 0.28% at 181p.